Description:
Treatment of pediatric acute lymphoblastic leukemia (ALL) has advanced and the overall
survival exceeds 80% nowadays. However the overall survival of high risk ALL remains 75-90%,
thus recent studies focus on treatment intensification according to the risk group. According
to the previous reports, we designed a multicenter prospective trial for pediatric ALL.
Title
- Brief Title: Treatment of Newly Diagnosed High Risk Acute Lymphoblastic Leukemia in Children
- Official Title: Treatment of Newly Diagnosed High Risk Acute Lymphoblastic Leukemia in Children
Clinical Trial IDs
- ORG STUDY ID:
KSPHO_HRALL
- NCT ID:
NCT02339350
Conditions
- Acute Lymphoblastic Leukemia
- Child
Interventions
Drug | Synonyms | Arms |
---|
high dose methotrexate | | Slow early responder group |
Intrathecal triple chemotherapy | | Slow early responder group |
Purpose
Treatment of pediatric acute lymphoblastic leukemia (ALL) has advanced and the overall
survival exceeds 80% nowadays. However the overall survival of high risk ALL remains 75-90%,
thus recent studies focus on treatment intensification according to the risk group. According
to the previous reports, we designed a multicenter prospective trial for pediatric ALL.
Detailed Description
Purpose of the study
1. For slow early responder (SER), to confirm if the augmented interim maintenance using
intravenous high dose methotrexate will improve the treatment outcome.
2. For slow early responder (SER), to confirm if removal of prophylactic radiotherapy will
relieve long term complications.
3. To predict the treatment response and prognosis high risk pediatric ALL by monitoring of
minimal residual disease (MRD).
Inclusion criteria
1. Diagnosis
1. Newly diagnosed B-precursor ALL meeting criteria 1.2
2. Newly diagnosed B-precursor ALL who was previously treated with steroid.
3. Newly diagnosed T cell ALL, excluding early T-cell precursor (ETP) leukemia
1.2 Initial WBC count
1. from 1 years old to 9 years old : WBC ≥ 50,000/μL
2. from 10 years old to 21 years old : Any WBC
3. from 1 years old to 21 years old : Any WBC with Testicular leukemia or CNS leukemia
(CNS3)
Exclusion criteria (who are classified as very high risk group) 2.1 Philadelphia chromosome
(+) or bcr/abl rearrangement (+) 2.2 Chromosome <45 by cytogenetics 2.3 Induction failure
(Day 28 M3 marrow (>25% blasts)) 2.4 t(4:11) (as identified by cytogenetics, FISH or
molecular studies) 2.5 Early T-cell precursor leukemia 2.6 Down syndrome ALL
Methods We will classify the patients to rapid early responder (RER) and slow early responder
(SER), according to the treatment response after induction remission and risk factors at
diagnosis. SER includes M2 (5-25% or leukemic cells at bone marrow exam) or M3 (25% or more
of leukemic cells at bone marrow exam) response at the 14th day of the start of induction
remission. If a patient showed total WBC count ≥ 100,000/μL, had testis or CNS (CNS 3)
involvement at diagnosis and was diagnosed as T-ALL, the patients will also be included into
the SER group.
Rapid early responders will undergo interim maintenance two times and reinduction for one
time. Slow early responders will undergo two times of interim maintenance treatment with high
dose intravenous methotrexate. For SER, adriamycin was previously administered only when
absolute neutrophil count and platelet was normal, but it will be administered without
restriction in this study. Both groups (RER and SER) will undergo maintenance chemotherapy
thereafter, with the treatment duration of 3 years from the 1st interim maintenance for boys
and 2 years for girls.
For SER group, prophylactic radiotherapy will not be done and it will be replaced by high
dose intravenous methotrexate and intensification of intrathecal chemotherapy by replacing
the intrathecal methotrexate to intrathecal cytarabine, methotrexate and hydrocortisone.
Trial Arms
Name | Type | Description | Interventions |
---|
Rapid early responder group | No Intervention | RER Consolidation BM exam on day 63: M1, M2 -> IM M3 or residual CNS ds or Bx proven extramedullary ds - off protocol
RER Interim Maintenance #1
RER Delayed Intensification
RER Interim Maintenance #2
RER Maintenance (12 weeks=84 days) | |
Slow early responder group | Experimental | Includes : SER, Testis(+), CNS 3, T-cell (non ETP), Initial PB WBC ≥ 100,000/μL
1. SER Consolidation
Intrathecal triple chemotherapy at d0, 7, 14, 21 2. SER Interim Maintenance #1
high dose methotrexate included
Intrathecal triple chemotherapy at d0, 28 3. SER Delayed Intensification #1
Intrathecal triple chemotherapy at d0, 28, 35 4. SER Interim Maintenance #2
high dose methotrexate included
Intrathecal triple chemotherapy at d0, 28 5. SER Delayed Intensification #2
Intrathecal triple chemotherapy at d0, 28, 35 6. SER Maintenance
Intrathecal triple chemotherapy at d0 | - high dose methotrexate
- Intrathecal triple chemotherapy
|
Eligibility Criteria
Inclusion Criteria:
1. Diagnosis
1. Newly diagnosed B-precursor ALL meeting criteria 1.2
2. Newly diagnosed B-precursor ALL who was previously treated with steroid.
3. Newly diagnosed T cell ALL, excluding early T-cell precursor (ETP) leukemia
1.2 Initial WBC count
1. from 1 years old to 9 years old : WBC ≥ 50,000/μL
2. from 10 years old to 21 years old : Any WBC
3. from 1 years old to 21 years old : Any WBC with Testicular leukemia or CNS leukemia
(CNS3)
Exclusion Criteria:
1. Philadelphia chromosome (+) or bcr/abl rearrangement (+)
2. Chromosome <45 by cytogenetics
3. Induction failure (Day 28 M3 marrow (>25% blasts))
4. t(4:11) (as identified by cytogenetics, FISH or molecular studies)
5. Early T-cell precursor leukemia
6. Down syndrome ALL
Maximum Eligible Age: | 21 Years |
Minimum Eligible Age: | 1 Year |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | event-free survival of SER group |
Time Frame: | 5 years from diagnosis |
Safety Issue: | |
Description: | |
Secondary Outcome Measures
Measure: | Number of adverse events |
Time Frame: | 5 years from diagnosis |
Safety Issue: | |
Description: | |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | The Korean Society of Pediatric Hematology Oncology |
Last Updated
January 16, 2015